Bank of America
CVKD icon

Bank of America’s Cadrenal Therapeutics CVKD Stock Holding History

Bank of America’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$7 – 5994
2025
Q4 		$7 Hold
1
– – ﹤0.01% 7216
2025
Q3 		$14 Sell
1
-13
-93% -$161 ﹤0.01% 8196
2025
Q2 		$169 Buy
14
+3
+27% +$45 ﹤0.01% 7870
2025
Q1 		$194 Buy
11
+1
+10% +$18 ﹤0.01% 7695
2024
Q4 		$145 Buy
10
+5
+100% +$72 ﹤0.01% 7657
2024
Q3 		$68 Hold
5
– – ﹤0.01% 7788
2024
Q2 		$38 Buy
+5
New +$35 ﹤0.01% 7894

Other funds holding CVKD

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
DWP
Destiny Wealth Partners Tavares, Florida $709M AUM 19.96% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Bank of America's CVKD Position: Q1 2026 in Review

Bank of America sold out of Cadrenal Therapeutics (CVKD) in Q1 2026, closing a stake of 1 share — an estimated $7 sold.

Bank of America first reported a position in CVKD in Q2 2024 and held it in 7 quarters. The position peaked at $194 in Q1 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q1 2026.

  • Bank of America reported no remaining Cadrenal Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 1 Cadrenal Therapeutics share in Q1 2026, an estimated $7.
  • Bank of America first reported a position in Cadrenal Therapeutics in Q2 2024 and held it in 7 quarters.
  • Bank of America's Cadrenal Therapeutics position peaked at $194 in Q1 2025.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.